Andrew Kung's research interests are centered on understanding basic mechanisms contributing to tumorigenesis, and extending basic research insights to the development of rationally designed anti-cancer therapeutic strategies.  He and his colleagues have a particular interest in aberrant signal transduction and transcriptional pathways associated with tumorigenesis.

Their research program extends from very basic tumor biology to the development of phase I clinical trials.  They utilize a variety of experimental approaches, including diverse molecular and cell biological techniques, viral vectors, gene expression profiling, mouse genetic models, in vivo cellular and molecular imaging, high-throughput screening assays, biochemistry, and proteomic analysis. They have ongoing internal and external collaborations with academic scientists, clinicians, and industry.  Active areas of research include:

• Role of hypoxia-regulated gene expression in tumorigenesis and angiogenesis.
    
• Discovering therapies targeting hypoxia-inducible transcription.
    
• Validation and development of therapies targeting IGF/IGF-1R.
    
• Elucidating mechanism of p300/CBP hematologic tumor suppression.
    
• Control of hematopoietic stem cell fate decisions by p300/CBP.
    
• Development of therapeutics targeting CXCR4 in brain tumors.
    
• Discovery of novel targets in acute leukemia.
    
• Development of therapies targeting histone modifying activities.
    
• In vivo cellular and molecular imaging for studying tumor biology.
    
• Development of clinically relevant preclinical models for drug evaluation.

Andrew Kung received his MD from Stanford University School of Medicine. He completed an internship and residency at Children's Hospital Boston and a fellowship at Children's Hospital Boston and Dana-Farber Cancer Institute.

Dr. Kung received the Howard Temin Award from the National Cancer Institute in 2001. He has been a Fellow in the Howard Hughes Medical Institute.